Yat Sun Or
2018
In 2018, Yat Sun Or earned a total compensation of $1.5M as Senior Vice President, Research & Development and Chief Scientific Officer at Enanta Pharmaceuticals, a 14% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $171,072 |
|---|---|
| Option Awards | $630,855 |
| Salary | $427,950 |
| Stock Awards | $275,275 |
| Other | $18,851 |
| Total | $1,524,003 |
Or received $630.9K in option awards, accounting for 41% of the total pay in 2018.
Or also received $171.1K in non-equity incentive plan, $428K in salary, $275.3K in stock awards and $18.9K in other compensation.
Rankings
In 2018, Yat Sun Or's compensation ranked 7,084th out of 14,244 executives tracked by ExecPay. In other words, Or earned more than 50.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,084 out of 14,244 | 50th |
Division Manufacturing | 2,724 out of 5,765 | 53rd |
Major group Chemicals And Allied Products | 1,026 out of 2,128 | 52nd |
Industry group Drugs | 865 out of 1,817 | 52nd |
Industry Pharmaceutical Preparations | 675 out of 1,391 | 52nd |
Source: SEC filing on January 18, 2019.
Or's colleagues
We found four more compensation records of executives who worked with Yat Sun Or at Enanta Pharmaceuticals in 2018.
News
Enanta Pharmaceuticals CEO Jay Luly's 2022 pay jumps 37% to $7.3M
January 20, 2023
Enanta Pharmaceuticals CEO Jay Luly's 2021 pay rises 2% to $5.3M
January 21, 2022
Enanta Pharmaceuticals CEO Jay Luly's 2020 pay rises 16% to $5.2M
January 21, 2021
Enanta Pharmaceuticals CEO Jay Luly's 2019 pay slips 1% to $4.5M
January 17, 2020
Enanta Pharmaceuticals CEO Jay Luly's 2018 pay rises 5% to $4.5M
January 18, 2019